352 related articles for article (PubMed ID: 33767588)
1. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract][Full Text] [Related]
2. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
3. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X.
Shen G; Lin Y; Yang X; Zhang J; Xu Z; Jia H
BMC Cancer; 2014 Jun; 14():393. PubMed ID: 24890815
[TBL] [Abstract][Full Text] [Related]
5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.
Zhao N; Wang R; Zhou L; Zhu Y; Gong J; Zhuang SM
Mol Cancer; 2014 Feb; 13():35. PubMed ID: 24565101
[TBL] [Abstract][Full Text] [Related]
7. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.
Zhang B; Wang X; Deng J; Zheng H; Liu W; Chen S; Tian J; Wang F
Cancer Lett; 2019 Sep; 459():50-58. PubMed ID: 31163195
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
9. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
10. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
11. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
[TBL] [Abstract][Full Text] [Related]
12. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.
Wang Y; Sun B; Zhao X; Zhao N; Sun R; Zhu D; Zhang Y; Li Y; Gu Q; Dong X; Wang M; An J
Oncotarget; 2016 Apr; 7(17):24383-401. PubMed ID: 27027434
[TBL] [Abstract][Full Text] [Related]
13. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
14. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
16. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
Wang D; Yang J
Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
[TBL] [Abstract][Full Text] [Related]
17. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.
Tang G; Zhao H; Xie Z; Wei S; Chen G
Bioengineered; 2022 Mar; 13(3):7829-7846. PubMed ID: 35291921
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
